You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》里昂升翰森製藥(03692.HK)目標價至29.55元 評級「跑贏大市」
阿思達克 09-02 12:48

里昂發表研究報告指,翰森製藥(03692.HK)上半年收入按年增21.9%至45.99億元人民幣,毛利率受到「4+7帶量集中採購」影響跌至91.7%,盈利則按年升24.3%至12.96億元人民幣,略低於該行全年預期。

不過該行指,由於公司今年將推出數個重要產品,包括:GLP-1及自主創新藥氟馬替尼(Flumatinib),預料2019年至2021年將可有強勁表現,分別錄得盈利24.4億元人民幣、30.96億元人民幣及38.79億元人民幣。同時,將目標價由23.78元升至29.55元,維持評級「跑贏大市」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account